| dc.contributor.author | Saglam, Sezer | |
| dc.contributor.author | Gurdol, Figen | |
| dc.contributor.author | Suzme, Rafi | |
| dc.date.accessioned | 2021-03-03T09:07:37Z | |
| dc.date.available | 2021-03-03T09:07:37Z | |
| dc.date.issued | 2009 | |
| dc.identifier.citation | Saglam S., Suzme R., Gurdol F., "Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, cilt.24, sa.3, ss.142-146, 2009 | |
| dc.identifier.issn | 0393-6155 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_1b5bd3b1-1c74-46a3-a9dd-f3328f30e328 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/23666 | |
| dc.identifier.uri | https://doi.org/10.5301/jbm.2009.4663 | |
| dc.description.abstract | Aim: Cytokines have been associated with symptoms and adverse outcomes in breast cancer. Overexpression of ERBB2 (c-erb-b2; formerly HER2/neu), which is a member of the epidermal growth receptor family, is associated with involvement of lymph nodes, large tumor size, high grade, steroid receptor negativity, aneuploidy, high proliferation rate, and low overall survival in breast cancer. The aim of the study was to examine whether ERBB2 amplification has any effect on circulating levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) in breast cancer patients. | |
| dc.language.iso | eng | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Biyoteknoloji | |
| dc.subject | Temel Bilimler | |
| dc.subject | BİYOTEKNOLOJİ VE UYGULAMALI MİKROBİYOLOJİ | |
| dc.subject | Mikrobiyoloji | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.title | Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients | |
| dc.type | Makale | |
| dc.relation.journal | INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS | |
| dc.contributor.department | İstanbul Üniversitesi , , | |
| dc.identifier.volume | 24 | |
| dc.identifier.issue | 3 | |
| dc.identifier.startpage | 142 | |
| dc.identifier.endpage | 146 | |
| dc.contributor.firstauthorID | 192663 | |